Oncocyte corp (OCX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS

-26,294

-22,426

-18,971

-16,717

-15,840

-15,754

-15,215

-19,150

-18,449

-19,375

-18,518

-14,206

-12,944

-11,168

-11,604

-11,426

-10,294

-8,735

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense

294

344

399

425

445

438

418

401

374

338

280

235

202

145

111

74

40

41

0

0

0

Amortization of intangible assets

0

-

-

-

-

121

182

242

242

242

242

242

242

242

242

242

242

242

0

0

0

Amortization of right-of-use assets and liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Pro rata loss from equity method investment in Razor

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of prepaid maintenance

64

37

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

3,246

2,995

2,609

2,132

1,818

1,479

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

1,461

1,257

1,147

922

0

0

0

-

-

-

-

Loss on sale of BioTime shares

-

-

-

-

-

-

-

-

-

-309

0

0

0

-

-

-

-

-

-

-

-

Unrealized gain (loss) on marketable equity securities

-280

-49

-511

-305

-439

-427

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Warrants issued to certain shareholders as inducement to exercise of warrants

-

-

-

-

-

-

-

-

-

4,074

0

0

0

-

-

-

-

-

-

-

-

Loss on sale of BioTime shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Warrants issued to certain shareholders as inducement of exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Amortization of debt issuance costs

82

59

45

55

67

77

88

97

102

83

0

0

0

-

0

0

0

-

-

-

-

Deferred income tax benefit

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

107

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amount due to Lineage and affiliates

1

-2,094

-2,110

-2,095

-2,106

2

9

-439

-502

-753

-153

702

1,139

2,007

1,677

1,176

1,134

1,557

0

0

0

Amount due to affiliates

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Prepaid expenses and other assets

161

202

172

337

637

11

-157

-95

43

-115

215

352

191

-101

171

82

179

274

0

0

0

Accounts payable and accrued liabilities

2,456

741

625

1,768

-465

1,002

-314

-108

851

-48

-92

580

514

229

1,315

768

1,049

1,042

0

0

0

Net cash used in operating activities

-19,867

-19,715

-16,865

-14,497

-15,614

-11,649

-12,537

-13,524

-12,848

-13,385

0

0

0

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of Insight Genetics, net of cash acquired

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,232

-

0

0

0

Net proceeds from sale of BioTime shares

-

-

-

-

-

-

-

-

-

934

934

934

502

0

0

0

0

-

-

-

-

Purchase of equipment

955

918

18

27

33

31

37

58

80

91

172

151

107

106

508

499

504

500

0

0

0

Security deposit and other

264

252

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-18,653

-12,415

-11,199

27

21

-31

-37

-58

352

843

0

0

0

-

-

-

-

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

311

-

0

0

0

Proceeds from exercise of stock options

-

943

943

945

950

58

203

409

645

610

600

393

192

218

83

86

46

4

0

0

0

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

7,774

7,774

2,031

2,031

0

0

0

0

-

-

-

-

Proceeds from sale of common shares

16,197

48,850

40,250

40,250

42,250

10,000

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Financing costs to issue common shares

324

3,288

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common shares received and retired for employee taxes paid

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of loan payable, net of financing costs

-

-

-

-

-

-

-

-

-

1,982

1,982

1,982

1,982

0

0

0

0

-

-

-

-

Repayment of loan payable

-

667

800

800

800

800

733

533

333

133

0

0

0

-

-

-

-

-

-

-

-

Repayment of financing lease obligations

337

454

454

443

434

381

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of capital lease obligation

-

-

-

-

-

-

-

-

-

265

219

182

161

114

0

0

0

-

-

-

-

Net cash provided by financing activities

17,539

47,868

36,687

40,002

42,238

12,114

12,371

15,232

13,756

9,968

0

0

0

-

-

-

-

-

-

-

-

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-20,981

15,738

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,695

-

0

0

0

NET INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

1,260

-2,574

-1,650

4,644

5,496

2,178

3,264

1,602

5,774

7,739

0

0

0

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES
Common stock issued for acquisition of Insight Genetics

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Initial fair value of contingent consideration at acquisition date

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Holdback liability

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred final commitment fee for bank loan

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-